Brokerages expect VIVUS, Inc. (NASDAQ:VVUS) to announce earnings of ($1.10) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for VIVUS’s earnings. VIVUS reported earnings of ($0.60) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 83.3%. The company is scheduled to announce its next quarterly earnings results on Tuesday, November 6th.
According to Zacks, analysts expect that VIVUS will report full year earnings of ($4.40) per share for the current year. For the next fiscal year, analysts expect that the firm will post earnings of ($5.70) per share. Zacks’ EPS calculations are an average based on a survey of research analysts that cover VIVUS.
VIVUS (NASDAQ:VVUS) last posted its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.08). The company had revenue of $14.96 million for the quarter.
VVUS has been the subject of a number of recent analyst reports. ValuEngine raised shares of VIVUS from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, September 12th. Zacks Investment Research raised shares of VIVUS from a “sell” rating to a “hold” rating in a research note on Friday, August 24th.
A hedge fund recently raised its stake in VIVUS stock. Renaissance Technologies LLC boosted its stake in VIVUS, Inc. (NASDAQ:VVUS) by 5.4% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,273,800 shares of the biopharmaceutical company’s stock after buying an additional 423,100 shares during the quarter. Renaissance Technologies LLC owned approximately 7.79% of VIVUS worth $5,833,000 at the end of the most recent quarter.
VIVUS stock opened at $4.41 on Friday. VIVUS has a 52 week low of $3.30 and a 52 week high of $9.90. The company has a debt-to-equity ratio of -10.60, a current ratio of 4.93 and a quick ratio of 4.26. The company has a market capitalization of $46.98 million, a P/E ratio of -1.52 and a beta of 0.58.
VIVUS, Inc, a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.
Read More: Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.